Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples